Overview

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Participants With Phenylketonuria

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-17

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the safety and tolerability of AG-181 in participants with Phenylketonuria (PKU).

Phase:

PHASE1

Details

Lead Sponsor:

Agios Pharmaceuticals, Inc.